Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis. Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) …

acute leukemia
platelet count
ruxolitinib
myelodysplastic syndromes
hypertension
  • 281 views
  • 30 May, 2022
  • 54 locations
  • 0 views
  • 01 Apr, 2021
  • 2 locations
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

thrombocytosis or unclassifiable with ring sideroblasts. Biological therapies, such as luspatercept, use substances made from living organisms that may stimulate or suppress the immune system in different ways

  • 0 views
  • 24 Mar, 2022
  • 1 location
A Phase II Study of CPX-351 Monotherapy in Acute Myeloid Leukemia (CPX-351 TA-SMP)

the first 10 years after diagnosis and in 4% to 8% of polycythemia vera (PV) and essential thrombocytosis (ET) patients within 18 years after diagnosis. The risk for leukemic transformation is

induction chemotherapy
gilbert's syndrome
cell transplantation
ejection fraction
cytarabine
  • 0 views
  • 23 Oct, 2022
  • 18 locations
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in …

trastuzumab emtansine
aptt
abiraterone
palbociclib
erlotinib
  • 2 views
  • 04 Oct, 2022
  • 1 location
Molecular Biology of Polycythemia and Thrombocytosis

Our study is designed to characterize the clinical picture and genetic pattern of Polycythemia and Thrombocytosis. The purpose of this project is to find a gene and its mutation that causes

  • 5 views
  • 23 Jan, 2022
  • 1 location
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.

platelet count
neutrophil count
hydroxyurea
thrombosis
interferon
  • 0 views
  • 27 Dec, 2021
  • 1 location
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance (SURPASS ET)

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.

ropeginterferon alfa-2b
platelet count
hydroxyurea
neutrophil count
interferon
  • 0 views
  • 25 Mar, 2022
  • 57 locations
Extension Study of Bomedemstat (IMG-7289) in Patients With Myeloproliferative Neoplasms

This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in patients with an MPN who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102 and IMG-7289-CTP-201 (referred to hereafter as 'feeder studies').

  • 0 views
  • 12 Jul, 2022
  • 9 locations
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

The purpose of this study is to assess the hematologic effects of IMG-7289 therapy in ET and PV patients who require platelet, White Blood Cell (WBC) or Red Blood Cell (RBC) control, and have failed at least one standard therapy.

platelet count
essential thrombocythemia
neutrophil count
polycythemia vera
interferon
  • 8 views
  • 03 May, 2022
  • 1 location